Riding the Wind, Full of Promise: 2023 World Digital Therapeutics Congress Successfully Concludes!

On August 26, 2023, byBeijing Danhuang Technology Co., Ltd.Hosted by,Chongqing Dongmaicheng Technology Co., Ltd.、Hainan Danhuang Technology Co., Ltd.Organized by,China Medical Device Industry Association, Digital Therapeutics Committee、UK Department for Business and Trade、AustradeSupport,AstraZeneca Investment (China) Co., Ltd.、Strategic Cooperation with Hainan Ecological Software Parkof2023 World Digital Therapeutics Conferenceconcluded successfully at the Hilton Haikou Meilan Hotel in Haikou, Hainan.

The conference, with“Pioneering a New Future for the Industrial Ecosystem,Total“Building a Community of Common Health for Mankind”as the theme, respectively established“Future Health Systems and the Global Community of Human Health,” “Digital Therapeutics and Oncology,” “Digital Therapeutics and Chronic Disease Management,” “Digital Therapeutics, Brain Science, and Cognitive Neuroscience,” “Digital Therapeutics and the Global Innovation Industry Ecosystem”Five Main Forums,The conference will bring together a distinguished array of guests, including academicians from China and abroad, senior executives from multinational pharmaceutical and medical device companies as well as leading domestic healthcare enterprises, CEOs of listed companies, renowned experts and scholars, representatives from innovative enterprises and member units of the Provincial Digital Therapeutics Industry Task Force, and delegates from medical institutions and universities. Together, they will discuss, co-create, and share insights on the future direction of global digital therapeutics.Exploring the Potential of Digital Therapeutics in Specific Clinical Scenarios to Unlock Greater Market Opportunities

01. Riding the Wind,Digital TherapeuticsGreat Potential

On August 25, at the opening ceremony, Xie Jing, Vice Governor of Hainan Provincial People's Government; Yu Xuejun, Member of the Party Leadership Group and Deputy Director of the National Health Commission; and Ning Guang, Academician of the Chinese Academy of Engineering and expert in endocrinology and metabolism, attended the conference and delivered speeches.Vice Governor Xie JingIn the opening remarks, it was expressed that Hainan hopes to join hands with all parties to jointly explore new pathways, theories, and rules for digital therapeutics, striving together to build Hainan into a global innovation island for digital therapeutics, a hub for innovative resources, and an industrial highland.Deputy Director Yu XuejunIn his address, he stated that countries around the world attach great importance to the integrated development of healthcare and information technology. Digital health has become a key pillar in advancing the healthcare sector, with digital therapeutics representing a core component of digital health.Academician Ning GuangIn his address, he stated that digital therapeutics can leverage technological means to break down data silos among standalone digital health solutions, thereby enabling whole-lifecycle health management for patients and advancing the establishment of an intelligent health management ecosystem.

Member of the Party Committee and Deputy Director, Hainan Provincial Health CommissionZhang YuhuiDelivering a keynote address titled “Hainan Riding the Wind: Progress in Building a Global Innovation Hub for Digital Therapeutics,” he provided a comprehensive overview of Hainan’s rapid advancement in the digital therapeutics industry over the past two years, along with his insights on its future development. He noted that an increasing number of regions across China are now strongly supporting digital therapeutics. As a pioneer in this field, Hainan will continue to accelerate its growth within the Free Trade Port and maintain its leading position in the development of digital therapeutics.

In this regard, multiple events were successfully held during the conference, including the release of the Hainan Initiative on Digital Therapeutics and the 2023 White Paper on Digital Therapeutics, the award ceremony for the “Best Innovative and Practical Enterprises in World Digital Therapeutics 2023,” and the launch ceremony for the implementation of innovative application scenarios and solutions for digital therapeutics in Hainan. These activities comprehensively demonstrated Hainan’s determination, confidence, and substantial achievements in developing its digital therapeutics industry.

It is reported that the “Hainan Initiative on Digital Therapeutics” was launched by the Party Secretary and Director of the Hainan Provincial Health CommissionZhou ChangqiangLed by the Director, multiple academicians and experts jointly released a 15-point initiative, signaling that Hainan will unite core stakeholders to accelerate the development of Hainan as an Innovation Island for Digital Therapeutics.

（(Hainan Initiative on Digital Therapeutics)

The “2023 World Digital Therapeutics Awards for Best Innovation and Practice Enterprises” was a concurrent event of the conference. Grounded in the innovation and practical ecosystem of digital therapeutics, the awards were open to digital therapeutics companies worldwide, aiming to identify emerging forces in the field and inject greater vitality into the robust development of Hainan’s digital therapeutics industry.Selected companies include ALSOLIFE, IBT Wujiang Technology, Luca Healthcare, Bingpian Technology, Boston, Daobo Medical, Enqi, Gezhi Health, Hejia Jiannao, JD Health, Jingcai Intelligence, Luming Health, Naodong Aurora, Ningdong Medical, Quanshi Technology, Senmei Medical, Shangyi Information Technology, Shijing Medical, Sumian Technology, Wangli Technology, Xiao Nan Ting Shuo, Xinjing Technology, Xuzhishi Technology, Yidu Tech, Pause Lab, Zheng’an Health, Zhi Lan Health, Zhisheng Technology, Zhizhong Medical, and Zhongxi Medical Technology (listed in alphabetical order, not in any particular order). Please read the full list for more details.Top 30 Digital Therapeutics Companies | Best Innovative and Practical Enterprises Announced at the 2023 World Digital Therapeutics Conference

(2023 World Digital Therapeutics Conference: Best Innovation and Practice Enterprises Announced)

“The Launch Ceremony for Innovative Application Scenarios and Implementation Solutions of Digital Therapeutics in Hainan” is a strong demonstration of Hainan’s substantive and systematic efforts to promote the implementation of digital therapeutics, whereinBeijing Jingshi Brain Science Research Institute Co., Ltd., Xiamen Hejia Jianbrain Intelligent Technology Co., Ltd.Selected for the 2023 Hainan Digital Therapeutics Initiative for Public Welfare—Pilot Project on Digital Therapeutics for Cognitive Rehabilitation in the Elderly，Shanghai Zhizhong Medical Technology Co., Ltd., Suzhou Yiduoyun Information Technology Co., Ltd., Tianjin Weiyi Digital Hospital Co., Ltd., Yidu Cloud (Hainan) Technology Co., Ltd.Selected for the “2+3” Health Service Package Project Fully Implemented in Hainan Province in 2023The ceremony witnessed the establishment and growth in Hainan of six digital therapeutics innovators selected for two projects, which will contribute to Hainan’s digital therapeutics solutions.

Following the grand opening ceremony, Academician of the Chinese Academy of EngineeringFan Daiming, 2013 Nobel Prize Laureate in Physiology or MedicineThomas C. Südhofand the Dean of VCBeatJiang TianjiaoDelivered keynote speeches on “Integration and Shift in the Development of Digital Health,” “How is 'Digital' Changing Biomedical Research and Drug Development?” and “Digital Therapeutics: A Great Era, Great Opportunities, and Great Transformation.”Academician Fan DaimingDigital healthcare represents an inevitable trend in the development of medicine, playing a unique role in addressing challenges such as population aging and chronic diseases. The China Anti-Cancer Association has formulated guidelines for tumor diagnosis and treatment and promoted their digital application, achieving significant results. Meanwhile, as digital healthcare becomes a major trend in medical advancement, China is at the forefront of this field globally.Thomas C. SüdhofIt is advocated that digital technologies can perform deep learning on data to uncover the mysteries of life and advance medical research. Although digital technologies present significant opportunities for biomedical research, challenges such as data quality and the commercialization of academic publishing persist. Addressing these issues requires concerted efforts from the scientific community to leverage digital technologies responsibly and fundamentally enhance research quality.Mr. Jiang TianjiaoDigital therapeutics are believed to generate downstream biological effects through cognitive and behavioral interventions, with their clinical value depending on the significance of these cognitive and behavioral factors in the disease context. Current commercialization faces challenges such as low penetration rates and relatively low unit prices, necessitating breakthroughs through price optimization and expansion of the covered population. In response to skepticism, it is essential to recognize the development trends of digital therapeutics, acknowledge the underlying patient needs, and maintain confidence in the industry’s growth.

02. When Medicine Meets Digital Technology, a Deep Integration Begins

In recent years, digital therapeutics (DTx) have experienced rapid growth globally, with their substantial value in empowering various sectors of the healthcare industry becoming increasingly evident. An examination of product pipelines currently undergoing clinical trials reveals that DTx now covers a wide spectrum of conditions, including amblyopia, autism spectrum disorder, Alzheimer’s disease, sleep disorders, and depression and anxiety. As the diversification of the DTx industry advances, companies in this sector are seeking common opportunities for growth. As a new incremental force within the healthcare ecosystem, they face a landscape where opportunities and challenges coexist. In light of this, the conference aims to comprehensively explore the next phase of innovative development in the DTx industry by examining key areas such as policy drivers, technological advancements and product development in niche segments, and the analysis of industrial ecosystems and innovative commercialization models.

Joining Hands to Build a Community of Common Health for Mankind

Diseases know no borders or nations; humanity is a community with a shared future, standing together in the same boat. The history of humanity’s struggle against disease teaches us that in the face of illness, the interests and fates of all countries are closely intertwined. Only by strengthening international exchange and cooperation and pooling global strengths can we maximally safeguard people’s lives and ensure the sustained and healthy development of nations. August 25CurrentlyMain Forum on the Future Health System and the Community of Common Health for Mankind & 2023 China Young Scholars Academic Conference on Health EconomicsFrom a global macro perspective, the discussion delves into topics such as Asia’s leadership in global health, the construction of healthcare service systems, trends in the concept of a global community of health for all, and the strategic significance of digital therapeutics to health systems. Experts attending the forum includeZhang Yuhui, Chairman of the Youth Health Economics Committee of the Chinese Society of Health Economics，Professor, The University of Hong Kong、David Bishai, Former President of the World Congress on Health Economics，Executive Director, China Health Development Research Center, Peking University、Meng Qingyue, Dean of the Hainan Institute for Health Development，Professor Liu Guoxiang, Harbin Medical University，Wang Yunping, Researcher at the Health Development Research Center of the National Health Commission，VCBeat Founder Li Datao。

Prof. David BishaiAdvocates for Asian countries to strengthen public health cooperation, cultivate talent, conduct high-quality research, collaborate with international organizations, promote the establishment of an Asian public health cooperation mechanism, and expand Asia’s influence in the global health sector.Director Meng QingyueIt is proposed to advance the reform of the healthcare system, adopt a people-centered approach, redirect the use of funds through institutional innovation, and meet the population’s health needs.Professor Liu GuoxiangPropose integrated resource services, implement diagnosis-related group (DRG) payment, and design performance incentives to establish an effective economic operation mechanism through regulatory assessment.Wang Yunping ResearchMemberIt points out that building a global community of health for all requires global solidarity and cooperation, the establishment of communities centered on security, development, and innovation, and an enhanced voice for developing countries.Mr. Li DataoIt is believed that the healthcare industry is undergoing a digital transformation, with digital health emerging as a new frontier, and future medical innovation may be led by China.Director Zhang YuhuiDigital therapeutics are regarded as a key technological and model innovation in the healthcare sector, capable of directly intervening in health and disease management and addressing the “impossible trinity” dilemma currently facing healthcare systems. China should leverage its market and technological strengths to rapidly nurture the digital economy industry through policy innovation, using digital therapeutics to lead a win-win upgrade in the health sector and contribute to building a global community of common health for all.

Digitalization Drives Transformation in Clinical Oncology Diagnosis and Treatment

Digital therapeutics can, on one hand, enhance cancer patients’ understanding of medication adherence within the context of precision medicine, and on the other hand, alleviate difficulties in accessing medical care due to distance or limited availability, thereby improving engagement with out-of-hospital follow-up, re-examinations, and return visits, ultimately enhancing their survival benefits. August 25On the afternoon of [Date], the main forum featured in-depth discussions on digital therapeutics and oncology, covering topics such as clinical research in drug development, optimization of treatment regimens, and practices in whole-course disease management. Distinguished guests attending the forum includedWang Jiejun, Professor and Chief Physician, Department of Medical Oncology, Shanghai Changzheng Hospital，Fang Yi, Director of the Phase I Clinical Trial Research Office, Peking University People's Hospital，Liu Peifeng, Deputy Director of the Shanghai Cancer Institute，Deputy Chief Physician, GCP Center, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences、David Wu, Director of Ethics，Shan Guohong, Senior Vice President of Takeda Pharmaceutical Company Limited and President of Takeda China，Yao Yixin, M.D., Chief Medical Officer for Greater China at Elsevier，Zhu Wei, CEO of Aikai Medical，Jia Yan, Director of the Healthcare and Life Sciences Division at China Renaissance(Host)。

(Guests on Digital Therapeutics and Oncology at the Main Forum)

Professor Wang JiejunDigital therapeutics are believed to facilitate the decentralization of medical resources, help address challenges in the comprehensive management of cancer patients both inside and outside hospitals, promote clinical research, and improve patient adherence, thereby achieving a win-win outcome for all stakeholders.Fang YiProfessorShare to, clinical trials have found that the new drug can sustainably treat autoimmune diseases such as rheumatoid arthritis by regulating the balance between regulatory T cells and effector T cells. It is recommended to leverage big data from digital health for multicenter studies and to explore the immunomodulatory potential of traditional Chinese medicine.Deputy Director Liu PeifengThis article summarizes the latest advances in nucleic acid drug development, with the aim of fostering industry-wide collaboration to drive digital innovation in nucleic acid therapeutics and improve survival rates for cancer patients.Deputy Director Wu DaweiShared the application of digital medical technologies in oncology clinical research, and pointed out that a characteristic of applying digital technologies in this field is the current lack of a fully digital infrastructure, with hybrid models being predominantly adopted.Mr. Shan GuohongIndicatesIn recent years, Takeda China has actively embraced digital trends in the pharmaceutical and healthcare sector, continuously exploring innovative technological solutions to accelerate patient benefits. A particularly representative initiative is the launch of myPKFiT, the first and only recombinant Factor VIII (FVIII) dosing guidance software approved for marketing by the National Medical Products Administration (NMPA) in China.Ms. Yao YixinThis article introduces how hospitals are currently responding to healthcare insurance reforms by establishing clinical care pathways, and how artificial intelligence can play a role in various stages of oncology diagnosis and treatment. It also discusses the product design of iCare Medical.Mr. Zhu WeiIt emphasizes three aspects: a foundation of extensive scientific research and evidence-based validation, an evidence-based knowledge system for cognitive behavioral interventions, and evidence-based treatment protocols.

Digital TherapeuticsBuildSmart Chronic Disease ManagementNew Management Model

Compared with traditional chronic disease management models, the digital management of chronic diseases has yielded positive outcomes. Concrete examples such as telemedicine, AI-assisted care, and electronic health records are fundamentally transforming how patients and physicians interact, share data, make treatment decisions, and influence patient prognosis. August 25In the afternoon, the main forum on Digital Therapeutics and Chronic Disease Management featured in-depth sharing on topics such as full-cycle management, applications of digitalization and artificial intelligence, and exploration of innovative models. Attendees at the forum includedWu Xifeng, Dean and Professor of the School of Public Health, Zhejiang University，Professor Weng Jianping, Chair Professor at the Division of Life Sciences and Medicine, University of Science and Technology of China，Wang Tao, Professor (Level II) and Doctoral Supervisor, Department of Nephrology, Peking University Third Hospital，Wang Jian, Executive Director of Cardiovascular, Renal, and Metabolic Commercial Innovation, Digital & Commercial Innovation Department, AstraZeneca China，Li Xin, Vice President of JD.com and General Manager of the Technology and Product Department at JD Health，Li Shaochun, Digital Strategy Scientist and CIO of Yunnan Baiyao Group, and General Manager of Yunnan Baiyao Smart Technology，Su Li, Vice President of Hengrui Yiduoyun and Head of Digital Therapeutics，Kang Cheng, CEO of Xuzhishi Technology，Mao Liwei, Marketing Director at Zhizhong Medical，Meng Xiangyu, Business Director of Luca Healthcare, Shen Ye, Founder and CEO of Langye Medical (Moderator)。

(Guests on Digital Therapeutics and Chronic Disease Management at the Main Forum)

Dean Wu XifengThe team is leading the construction of the Healthy Zhejiang Million-Person Cohort Project, striving to build a world-class, domestically unique high-level scientific and technological innovation platform for public health and general wellness. Through this platform, they aim to advance the development of new technologies, methods, and systems for disease prevention, diagnosis, treatment, and prognosis, as well as health management, across the entire “prevention–diagnosis–treatment–prognosis” continuum.Professor Jianping WengIt is believed that although China has a large population of patients with diabetes, the prevailing trends are unlikely to be reversed in the foreseeable future. Digital technology offers possibilities for personalized health management. The professor is establishing a Joint Laboratory for Digital Health with iFLYTEK to develop digital solutions for diabetes.Professor Wang TaoThe core of chronic disease management lies in the development of specialized departments at district and county-level hospitals. Top-tier experts should support grassroots healthcare providers to form specialized disease alliances. By integrating multi-party resources and leveraging digital platforms to facilitate shared decision-making at the primary care level, chronic disease management can be effectively promoted.Mr. Wang JianSharing: AstraZeneca is committed to supporting the development of integrated in-hospital and out-of-hospital diagnosis and treatment solutions through digital healthcare innovation, while expanding coverage to various channels that enhance patient accessibility, such as pharmacies.Mr. Li XinIntroduction: JD Health has collaborated with multiple medical institutions to conduct a series of clinical trials and applied research studies, and has participated in numerous major scientific research projects.Mr. Li ShaochunThis article elaborates on the applications of large language model (LLM) technology in the healthcare and pharmaceutical sectors, as well as its significance for the continuous digital transformation of pharmaceutical enterprises.Ms. Su LiThis article introduces diabetes diagnosis and treatment tools designed to assist primary care physicians, including risk assessment for diabetic patients, recommendations for precision treatment plans, and personalized health education. It also highlights Hengrui Medicine’s digital therapeutics portfolio spanning multiple therapeutic areas, one of which is poised to become the first digital therapeutic approved for the treatment of anxiety disorders.Mr. Kang ChengBy integrating AI technologies, the product can leverage recommendation algorithms and deep learning to create personalized treatment plans for individual patients, thereby harnessing technological advantages to enhance both efficiency and efficacy.Mr. Liwei MaoEstablish independent chronic disease management scenarios, integrate data from within and outside hospitals, and build a national chronic disease management network. Utilize digital therapeutics to improve patient adherence and enable remote diagnosis and treatment.Mr. Meng XiangyuShare to Luca is committed to leveraging highly accessible data to build medical solutions centered on digital biomarker technology, supporting clinical drug trials and extending related outcomes to post-marketing digital companions, thereby further providing healthcare services to industries such as internet-based healthcare, physical examinations, and elderly care.

Digital Therapeutics Accelerate Brain Science and Cognitive Neuroscience Technologies

Brain-related disorders have become an unavoidable social issue, with enormous market demand; the rise of digital therapeutics offers a novel treatment approach for these conditions. August 25In the afternoon, the main forum on Digital Therapeutics, Brain Science, and Cognitive Neuroscience featured in-depth sharing on topics such as explorations in diagnostic and therapeutic innovation, as well as the development and application of innovative platforms. The guests attending the forum includedJiang Tianzi, Director of the Brain Network Group Research Center at the Institute of Automation, Chinese Academy of Sciences; Foreign Member of Academia Europaea; IEEE/IAPR/AIMBE Fellow，Zhang Mingjun, Tenured Professor and Doctoral Supervisor at Tsinghua University，Professor Xue Gui, State Key Laboratory of Cognitive Neuroscience and Learning, Beijing Normal University，Yan Weiqi, Professor at Zhejiang University and Dean of the Hangzhou Medical College Institute of Life Sciences and Health Technology Innovation，He Xingzhi, Associate Research Fellow in Professor Ma Huan’s Research Group at Zhejiang University，Zhang Rong, Co-founder of the Autism Research Center at Peking University Health Science Center and Executive Vice Chairman of the Beijing Neuroscience Society，Fellow of the American Psychological Association, Fellow of the Hong Kong Psychological Society, Professor at The Education University of Hong Kong, and Chief Scientist at Xiamen Hejia Brain Health, Chen Zhixuan，Cao Qun, Chairman and General Manager of Xinjing Technology，Wu Shaohui, COO of the Dallas Sleep Health Group, USA，John Krakauer, Professor of Neurology, Neuroscience, and Physical Medicine and Rehabilitation at Johns Hopkins University School of Medicine, Fan Fangfang, Investment Partner of the Medical Business Division at Guoke Longhui (Moderator)。

（Guests on Digital Therapeutics, Brain Science, and Cognitive Neuroscience at the Main Forum)

Academician Jiang TianziBrain atlas mapping involves parcellating the brain into structurally and functionally distinct regions, representing an interdisciplinary field at the intersection of information science and neuroscience. The Brainnetome Atlas integrates fine-grained brain parcellation with connectomic mapping, offering a novel in vivo brain atlas characterized by more refined regional delineations and new patterns of subregional anatomical and functional connectivity.Prof. Zhang MingjunResearch is currently underway on digital diagnostic and therapeutic technologies based on flexible brain-computer interfaces and nonlinear neural dynamics. Leveraging micro-nano technology and neural dynamics theory, we have successfully developed a high-throughput bidirectional interaction system that spans from minimally invasive flexible electrodes to chips and miniature wireless transmission systems.Prof. Xue GuiThe future trend in non-pharmacological diagnosis and treatment of neuropsychiatric disorders is envisioned as a paradigm that leverages big data and multimodal research to achieve precise subtyping of complex conditions, employs comprehensive multimodal therapeutic strategies, and utilizes real-world studies to develop interventions with greater practical feasibility and ecological validity.Prof. Yan WeiqiDigital therapeutics in digital hospitals are primarily software-driven, evidence-based intervention programs that have been scientifically validated to treat, manage, or prevent diseases. Their ultimate value lies in their efficiency, precision, low resource consumption, safety, and personalization.He XingzhiResearcherEmotion and cognition are characteristic mental activities of higher animals, and their impairments constitute important clinical manifestations of numerous brain disorders, including depression. Currently, therapeutic options for emotional and cognitive impairments are limited and yield suboptimal outcomes, primarily due to a lack of fundamental research into their pathogenic mechanisms.Prof. Zhang RongCurrent emerging technologies in research leverage magnetic resonance imaging to extract structural and functional network feature profiles in children with autism spectrum disorder for assisting clinical diagnosis, and employ transcutaneous acupoint electrical stimulation—a technique evolved from traditional acupuncture principles—to improve social interaction and sensory processing, as well as to alleviate anxiety in affected children.Prof. Chen ZhixuanCurrent research indicates that early therapeutic intervention for individuals with Mild Cognitive Impairment (MCI) can, to a certain extent, mitigate disease progression. Hejia Jiannao’s launch of China’s first self-administered MCI screening software is precisely based on this concept.Mr. Cao QunHighlighting Xinjing’s flagship product—the Virtual Reality Psychological Rehabilitation System—this solution integrates traditional psychotherapies, such as music therapy and hypnotherapy, with modern virtual reality and biofeedback technologies to provide patients with a safe and effective treatment option.Wu ShaohuiDr.Speaking ofSleep health issues are becoming increasingly prevalent in society, leading to a range of other chronic diseases. However, since ventilators cannot be sold in public medical institutions in China and there is a lack of guidance from professional physicians, there are still many practical challenges in the implementation and management of ventilator therapy for obstructive sleep apnea (OSA).Professor John KrakauerIt is anticipated that, in the foreseeable future, more offline venues will feature such treatment points integrating digital neuromodulation technologies, which will also represent the future trend in the treatment of patients with neurological disorders.

Industry Ecosystem Trends Emerge: The Collision of Global Frontiers and Innovative Practices

With strong support from the digital transformation of healthcare, digital therapeutics are opening up new horizons for the medical field. How to connect various stakeholders in the digital therapeutics industry, converge hot topics, showcase the latest practices and cutting-edge developments, and promote the co-prosperity of the digital therapeutics ecosystem has become a critical challenge facing the industry. August 26The Digital Therapeutics and Global Innovation Industry Ecosystem Main Forum conducted in-depth discussions through two segments—Digital Empowerment and Digital Exploration—focusing on collaboration within the healthcare ecosystem, multi-industry chain empowerment, global implementation of industries, technological innovation in products and technologies, and commercial practices. Distinguished guests attending the forum includedZhang Yuhui, Deputy Director of the Hainan Provincial Health Commission and Deputy Director of the Health Development Research Center of the National Health Commission，Zhang Jing, Vice President of the Yuhang Campus of The First Affiliated Hospital, Zhejiang University School of Medicine，Xie Chen, Deputy Director of the Strategic Development Department, Institute for Global Health and Development, Peking University，Ding Caihui, General Manager of the Industrial Business Group, Hainan Eco-Software Park，Yao Zhiguo, Deputy General Manager of Haikou Fuxing City Internet Information Industrial Park，Gao Yunlong, General Manager of Zhilan Health，Liu Chongsheng, Secretary-General of the Digital Therapeutics Committee of the China Association for Medical Device Industry，Chen Yun, Business Development Manager for Medical Devices, BSI China，Tao Hua, Technical Director of Mindray，Hong Shun, Manager of the Medical Products Division, CSA Group，Yang Yifei, Director of the Overseas Affairs Department at Tigermed Jietong，Mike McCourt, Life Sciences and Healthcare Attaché, UK Department for Business and Trade，Andrea Myles, Deputy Consul-General (Commercial), Consulate General of Australia in Guangzhou; Senior Commercial and Investment Commissioner, Austrade，Eva Verstraelen, Commercial Consul, Flanders Investment & Trade, Consulate General of the Kingdom of Belgium in Guangzhou，Chen Kaishen, CEO of Zhongxi Medical Technology，Marie Chavanon, Director of Digital Health and Partnerships, Greater China, Sanofi，Li Lisha, Head of PHC Strategy at Roche Pharmaceuticals，Welt，Head of US market，Danny Jooyoung Kim，JOGO Health，President，Siva Nadarajah，Christopher Gill, Deputy Director of Product Development Strategy, ResMed Headquarters (Australia)，Founder and CEO of Uscom Rob Phillips，NX10 CEO Aidyn Kussainov，Wang Zilin, Founder of MEDii Health，Yang Junjun, Director of Business Development for China and the Asia-Pacific Region at Congenica，Fu Le, Chief Business Officer of Zhiyu Health。

(Guests of the Main Forum on Digital Therapeutics and the Global Innovation Industry Ecosystem)

The forum session on the morning of the 26th focused on digital empowerment of the industrial ecosystem.Zhang YuhuiDirectorThe opening remarks highlighted the importance of building an innovative ecosystem for digital therapeutics and Hainan’s advantages in establishing itself as an Innovation Island for digital therapeutics. It expressed the expectation that Hainan will take the lead in cultivating such an innovation ecosystem, thereby supporting the development of a World Digital Therapeutics Innovation Island and positioning digital therapeutics as a new engine for the leapfrog development of Hainan’s healthcare sector and industry.Zhang JingVice PresidentThe interconnection between pathology and digital therapeutics was discussed. To address emerging challenges, the Ministry of Industry and Information Technology (MIIT) and the National Medical Products Administration (NMPA) have jointly established an artificial intelligence medical device platform. By integrating the functional modules of digital pathology software, this initiative aims to achieve precise diagnosis and facilitate end-to-end management throughout the digital therapeutics workflow. The integration of digital healthcare with both basic medical insurance and commercial insurance is key to realizing large-scale commercialization of digital healthcare solutions.ThanksChenDeputy DirectorThis article introduces the common challenges facing global healthcare systems and the rise of value-based care, and elucidates how the integrated innovation of digital health with public health insurance and commercial insurance has become a core driver for the development of value-based care.Ding CaihuiMr.It is mentioned that the park serves as the core hub for Hainan’s development of the digital health industry, bringing together the vast majority of China’s internet healthcare, health finance, pharmaceutical e-commerce, and digital supply chain enterprises for pharmaceuticals and medical devices, and has established the nation’s first blockchain pilot zone.Yao ZhiguoMr.Shared the planning and development opportunities of the Fuxing City Digital Therapeutics Industry Base, particularly for digital therapeutics companies. In addition to facilitating the implementation of digital therapeutics projects, the industrial park also provides full-process operational services.Gao YunlongMr.It is pointed out that data, algorithms, and services are the defining characteristics of digital therapeutics. Companies must prioritize early-stage data accumulation, mid-stage data collection and research, and real-world studies, while continuously enhancing their algorithms and core models. Only in this way can digital therapeutics deliver greater value to enterprises and make significant contributions to the industry in the future.Mr. Liu Chongsheng, Mr. Chen Yun, Mr. Tao Hua, Mr. You Hongshun, Ms. Yang YifeiThe dialogue shared insights into the regulatory challenges faced by digital therapeutics across various regions worldwide, as well as issues related to data security and cybersecurity. It was recommended that enterprises stay informed of the latest regulatory requirements in each region, strengthen industry exchange and collaboration, and proactively address global regulatory challenges.

The forum session on the afternoon of the 26th focused on digital exploration of the industrial ecosystem.Mike McCourtThis article highlights the United Kingdom’s leading position in the life sciences sector and the government’s strong support for digital therapeutics.Andrea MylesShared the development status, ecosystem, and cooperation opportunities of Australia’s digital health industry.Eva VerstraelenThis article introduces the leading position of the Flanders region of Belgium in the medical field and the preferential policies offered by its government.Mr. Chen Kaishen, Marie Chavanon, Ms. Li Lisha, Danny Jooyoung Kim, Siva NadarajahDiscussions centered on the application and commercialization pathways of digital therapeutics (DTx) in the healthcare sector, sharing insights and experiences from explorations in this field. Topics covered included the concept and definition of DTx, collaboration models with pharmaceutical companies, as well as commercialization and regulatory pathways.Christopher GillResMed has been continuously increasing its investments in digital health and digital therapeutics, aiming to introduce more outstanding digital solutions to China to support the development of China’s digital health industry and improve public sleep health.Rob PhillipsShared experiences on how Uscom’s diverse product portfolio, empowered by digital tools, facilitates precision diagnosis and treatment as well as telemedicine, while enhancing efficiency and patient outcomes.AidynIt is believed that every time we pick up our smartphones, we invisibly become payers for digital health services, generating data on our physical health. By detecting neural signals to determine whether one is suffering from mental decline or other psychiatric disorders, and by providing early warnings and predictions of adverse health events, such digital health solutions prove highly effective.Wang ZilinMs.Four Digital Applications in Cross-Border Medical Care: Electronic Medical Records, Lossless Image Restoration and Adaptation, Overseas Physician Selection, and Bill Payment and SettlementYang JunjunMr.Share Share to Congenica has established a highly scalable, automated platform for genetic disease analysis based on artificial intelligence and big data, and has developed its own AI algorithms.FuleMr.Shared the core focus of Zhiyu Health’s work: on one hand, providing digital primary healthcare services for specific diseases, including disease-specific patient-physician management, private-domain patient engagement, and specialty academic and research support; on the other hand, offering digital value-added services outside hospital settings, including intelligent blood pressure management, out-of-hospital rehabilitation, and empowerment of out-of-hospital testing.

After two days of sharing perspectives and engaging in interactive exchanges, experts and scholars from various sectors have gained a deeper understanding of the development trends and current landscape of the global digital therapeutics industry, as well as the exploratory practices in innovative technologies. Industry practitioners attending the conference have expressed confidence and hope for the future of the digital therapeutics sector. It is believed that the healthcare industry will grow more rapidly and robustly with the empowerment of digitalization. The holding of this “World Digital Therapeutics Conference” will also accelerate the construction of a new paradigm in healthcare, jointly contributing to a new future for the global healthcare innovation industry.